Effects of dose and schedule on the efficacy of ethyol: Preclinical studies

[11] Amifostine - An update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome [J]. DRUGS, 2001, 61 (05) : 641 - 684

[12] Davidson D.E., 1980, RAD SENSITIZERS THEI, P309

[13] Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity [J]. SEMINARS IN ONCOLOGY, 2002, 29 (06) : 14 - 21

[14] Grdina D J, 2000, Drug Metabol Drug Interact, V16, P237

[15] Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) : 2101 - 2112

[16] Randomized phase III study chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: Preliminary results [J]. SEMINARS IN RADIATION ONCOLOGY, 2002, 12 (01) : 46 - 49

[17] Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (11) : 2226 - 2233

[18] Murley JS, 2002, RADIAT RES, V158, P101, DOI 10.1667/0033-7587(2002)158[0101:DCAEOS]2.0.CO

[19] 2

[20] PARKINS C S, 1983, Radiotherapy and Oncology, V1, P159, DOI 10.1016/S0167-8140(83)80018-8

[11] Amifostine - An update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome [J]. DRUGS, 2001, 61 (05) : 641 - 684

[12] Davidson D.E., 1980, RAD SENSITIZERS THEI, P309

[13] Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity [J]. SEMINARS IN ONCOLOGY, 2002, 29 (06) : 14 - 21

[14] Grdina D J, 2000, Drug Metabol Drug Interact, V16, P237

[15] Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) : 2101 - 2112

[16] Randomized phase III study chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: Preliminary results [J]. SEMINARS IN RADIATION ONCOLOGY, 2002, 12 (01) : 46 - 49

[17] Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (11) : 2226 - 2233

[18] Murley JS, 2002, RADIAT RES, V158, P101, DOI 10.1667/0033-7587(2002)158[0101:DCAEOS]2.0.CO

[19] 2

[20] PARKINS C S, 1983, Radiotherapy and Oncology, V1, P159, DOI 10.1016/S0167-8140(83)80018-8